Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6197945 | PMC |
| http://dx.doi.org/10.1016/j.jdcr.2018.07.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An Unusual Presentation of Cutaneous Bullous Lupus.
Cureus
November 2024
Rheumatology, Cooper University Health Care, Camden, USA.
Drug-induced lupus erythematosus (DILE) is an autoimmune reaction that results in symptoms of polyarthralgia, fever, and cutaneous lesions and other manifestations. Several drugs have been documented to cause this disease, including procainamide, isoniazid, methyldopa, penicillamine, and hydralazine. Systemic lupus erythematosus (SLE) manifestations often occur after the patient has been taking the drug without complications for months to years.
View Article and Find Full Text PDFBullous Pemphigoid Induced by Cefixime: A Rare Side Effect.
Cureus
November 2024
Internal Medicine and Clinical Immunology, Lebanese Hospital Geitaoui - University Medical Center, Beirut, LBN.
Bullous pemphigoid (BP) is the most prevalent autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and manifests with pruritus and localized or, most commonly, generalized bullous lesions. Numerous studies have established the association between BP and oral antidiabetic agents, particularly dipeptidyl peptidase 4 (DPP4) inhibitors, diuretics, and certain antibiotics, notably levofloxacin and cephalexin.
View Article and Find Full Text PDFMilia En Plaque After Bullous Pemphigoid: An Unusual Sequela.
Cureus
November 2024
Dermatology, Texas Tech University Health Sciences Center, Lubbock, USA.
We present the case of a 36-year-old paraplegic woman with a history of spinal cord injury who developed a generalized blistering rash, later diagnosed as bullous pemphigoid (BP). During her hospitalization, she was treated with prednisone and rituximab infusions, transitioning to maintenance therapy with topical steroids, doxycycline, and nicotinamide. A year later, she presented with concerns about a BP flare on her feet.
View Article and Find Full Text PDFAssessing usability of electronic patient-reported outcome measures in older people with and without a rare dermatologic disorder.
J Patient Rep Outcomes
December 2024
eCOA Science, Clario, Geneva, Switzerland.
Background: Robust and well-defined data collection is important when using electronic patient-reported outcome measures (ePROMs) in clinical studies. Questions have been raised as to whether older age may be a barrier to data collection due to patients' unfamiliarity with electronic devices. Older adults may also have underlying health conditions that affect their ability to fill out patient-reported outcome measures (PROMs) on electronic devices.
View Article and Find Full Text PDFAnalysis of Hospitalization Cases for Filler Injection Complications: A Five-Year Retrospective Study Among Iranian People.
J Cosmet Dermatol
December 2024
Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Introduction: The skin is the largest organ system with many important clinical functions. Due to the increase in demand for cosmetic procedures and consequently the increase in complications from filler injections, this research aims to review the hospitalization cases involving filler complications.
Methodology: This study retrospectively and cross-sectionally reviews patient records hospitalized between the years 2016 to 2020, focusing on demographics (age, gender, residence), type of filler, type of complications, onset and duration of complications, duration of hospital stay, the person who administered the injection, and treatment outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!